Guggenheim raised the firm’s price target on Centessa to $10 from $9 and keeps a Buy rating on the shares. Management continues to execute operationally, with the SerpinPC PRESent-2 registrational trial ongoing and LB101 Phase 1/2a dose escalation under way, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CNTA:
- Centessa price target raised to $11 from $6 at SVB Securities
- Centessa reports Q2 EPS (26c), consensus (49c)
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
- Is CNTA a Buy, Before Earnings?
- Centessa price target raised to $15 from $11 at BMO Capital